Movement Alert|AKESO rises 3.28% in Regular Trading, buyback support helps sentiment rebound after FDA setback

Market Focus11-17

On November 17, AKESO rose 3.28% intraday in Regular Trading, trading at HK$66.25, with turnover of HK$220 million.

The clearest catalyst for the rebound was the company’s disclosed share purchase by the trustee on November 16, totaling about 336,000 shares for roughly HK$21 million, funded by existing available cash, with the board stating this reflects confidence in business prospects and future outlook.

This followed sharp pressure after ivonescimab’s US biologics license application received a Complete Response Letter from the FDA. The company had said operations remain normal, while management moved quickly to communicate with investors. The buyback-related purchase appears to have provided near-term support for sentiment after the prior selloff tied to delayed US commercialization visibility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment